secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001062993-25-002033
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting
--------------------------------------------------------------------------------

- Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.
- Proceeds to fund Phase 2 BCC trial, expand to pivotal trial and other non-melanoma skin diseases.
- Yorkville received $25k structuring fee and 105,840 commitment shares.
- Board approved voluntary delisting from TSXV; shares continue on Nasdaq (MDCX).
- Drawdowns require effective SEC registration statement; 19.99% cap and 4.99% beneficial ownership limit apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/0001062993-25-002033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-002033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer